a lot of scissors
Biotech

Ultragenyx shrinks workforce and axes assets to halve R&D spend

Ultragenyx is laying off 20% of its staff and axing drug development programs to cut its annual R&D budget to half of the amount it spent in 2025.
Nick Paul Taylor Nov 4, 2026 5:19am
The cost of waiting What reaching clinical proof-of-concept sooner means for biotech cash burn

The cost of waiting: how early proof-of-concept shapes cash burn

Brought to you by Altasciences
Sanofi headquarters Sanofi

Sanofi scraps Nurix program 2 months after entering clinic

Nov 4, 2026 5:02am
Doustdar

Novo aims for deals to ‘close some gaps’ as misfires hit profits

Nov 4, 2026 4:01am
AbbVie Oxford

AbbVie invests £120M in UK, including new R&D headquarters

Nov 4, 2026 2:31am
Money present

Rhythm drums up LG obesity license to as much as $855M

Nov 3, 2026 9:32am
More News

AbbVie drops ph. 2 solid tumor drug over ‘limited benefit’

Nov 3, 2026 8:38am

Pfizer trims obesity pipeline, axes phase 2 lung disease asset

Nov 3, 2026 8:02am

Novartis scraps $800M BioArctic brain collab after barely a year

Nov 3, 2026 4:53am

FDA grants uniQure priority review of its Huntington’s drug

Nov 2, 2026 4:12pm